• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

31.05 +0.72 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spyre Therapeutics, Inc. - Common Stock

News headline image
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 04, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
November 04, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
October 29, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
October 24, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
October 15, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
October 13, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
October 13, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
September 15, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
December 03, 2024
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap